Last reviewed · How we verify
NCT05303506
Study on the Effect of Different Risk Factors on the Growth Parameters of Thalassemic Patients in Assiut (AUCH)
trial testing serum ferritin and AST in Thalassemia Major in 50 participants. Status unknown.
2 December 2023
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 2 July 2022 |
| Primary completion | 2 December 2023 |
| Estimated completion | 2 March 2024 |
Drugs / interventions tested
- serum ferritin and AST
Conditions studied
- Thalassemia Major — all drugs for Thalassemia Major →
Sponsor
Assiut University
Who can join
Adults 1 to 16, any sex, with Thalassemia Major. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the effect of different risk factors on the growth parameters of thalassemic patients in Assiut University children Hospital (AUCH) In order to help in decreasing the morbidity and mortality resulting from iron overload and improving the quality of life for thalassemic patient
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05303506
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thalassemia Major
Currently open trials in the same condition.
- NCT07112703 — Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia M · NA · recruiting
- NCT06931912 — Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents With Thalassemia · NA · recruiting
- NCT06490627 — Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia · Phase 2 · recruiting
- NCT06041620 — Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells · NA · recruiting
- NCT06913634 — Study to Evaluate the Long- Term Safety and Efficacy of Luspatercept in Subjects Who Received at Least One Dose of Luspa · active not recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05303506 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 31 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05303506.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing